Evidence map›Paper›PMID 41836416›Full record

ReviewFrontiers in immunology2026

The Regnase pathway: a core axis in immune regulation and inflammatory disease.

Luca Muzio, Davide Ferrati, Eleonora Colombo, Claudia Molinaro

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luca MuzioNeuroimmunology Unit, Department of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Davide Ferrati *Neuroimmunology Unit, Department of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Eleonora Colombo *Neuroimmunology Unit, Department of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Claudia Molinaro *Neuroimmunology Unit, Department of Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Regnase/MCPIP ribonucleases are involved in the regulation of immune homeostasis, by degrading RNA transcripts that encode inflammatory and regulatory proteins. This review highlights their molecular architecture, catalytic mechanisms, and intricate regulatory networks that orchestrate innate and adaptive immunity. This article presents a narrative review of the literature on distinct physiological roles of individual family members and how their dysfunction drives inflammatory, autoimmune, fibrotic, metabolic, and neoplastic disorders across multiple tissues. Although Regnase family members exhibit some functional redundancy, each also possesses distinct, non-overlapping roles. Regnase-1 restrains cytokine production and along with Regnase-2 modulates neuroinflammation. Both Regnase-3 and Regnase-4 possess homeostatic functions although they are also involved in orchestrating interferon and myeloid signaling and contribute to immune regulation and tumor suppression. We also examine emerging therapeutic strategies targeting Regnase activity, including antisense oligonucleotides to enhance Regnase-1 expression, gene- and RNA-based delivery approaches, and selective inhibition of Regnase-1 in T cells to boost cancer immunotherapy. Together, these findings underscore Regnase proteins as central post-transcriptional checkpoints in immunity and highlight their potential as targets for treating autoimmune disease, chronic inflammation, fibrosis, and cancer.

Indexed as

InflammationRibonucleasesAdaptive ImmunityAnimalsAutoimmune DiseasesHumansImmunity, InnateImmunomodulationSignal TransductionTranscription FactorsRibonucleasesTranscription FactorsZC3H12A protein, humancytokine homeostasisimmune tolerance and inflammationpost-transcriptional regulationRegnase-1RNA-binding proteinsZC3H12A/MCPIP1

Identifiers

PMID41836416
PMCPMC12982082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.